Peregrine Pharmaceuticals Provides Corporate Update

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses

- Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued Growth Expected to Lead to Future Sustainable Profitability in 24 Months -

- Drug Development Strategy to Focus on Early Stage Clinical Trials of Bavituximab and Immuno-Oncology (I-O) Combinations -

TUSTIN, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM ) (NASDAQ: PPHMP ), a company focused on continued revenue growth from its contract manufacturing business and developing its novel immuno-oncology products, today provided a corporate update highlighting the company’s operational strategies and latest developments.  The company’s contract manufacturing subsidiary, Avid Bioservices, continues to experience significant organic growth, generating $44 million in revenue for fiscal year (FY) 2016 compared to $26.7 million in contract manufacturing revenue in FY 2015. Peregrine expects to continue to have double digit contract manufacturing revenue growth, and for FY 2017, the company is providing revenue guidance of $50-55 million for Avid, due in part to the revenue backlog of $56 million under committed contracts from existing clients. Peregrine expects this trend, driven by increasing client demand and several ongoing expansion initiatives, to lead to future sustainable profitability for the company in 24 months. 

“The past several months have been a busy and productive time at Peregrine as we work to optimally position the company for future success with both our contract manufacturing and drug development businesses.  We are very pleased that Avid exceeded its revenue projections for fiscal year 2016 and excited for what we expect will be continued growth for that business,” said Steven W. King, president and chief executive officer of Peregrine.  “At the same time, we continue to work to advance our phosphatidylserine (PS)-targeting platform.  In order to move toward overall profitability while continuing to generate valuable clinical data, we will focus our future development efforts on small, early stage clinical trials evaluating combinations of bavituximab and immuno-oncology (I-O) agents.  This strategy will be supported through our current and future collaborations, which we believe will efficiently generate the clinical data required to identify and pursue the most valuable opportunities for bavituximab.”

Contracting Manufacturing Highlights:

  • Avid Bioservices exceeded its full FY 2016 revenue target of $40 million, generating $44 million in contract manufacturing revenue.   
  • The company today announced full FY 2017 revenue guidance for Avid Bioservices of $50-55 million.  
  • Avid currently has a revenue backlog of $56 million under committed contracts from existing clients.  
  • The recently commissioned second manufacturing facility has completed its initial process validation runs and is ramping up to conduct multiple new process validation runs for three current clients.  Process validation is a critical element in preparing a facility to launch commercial manufacturing activities.  As such, this milestone moves Peregrine a key step closer to realizing revenue from commercial production from this new manufacturing suite.  
  • Based on significant client demand, Peregrine is in the process of designing a third manufacturing facility focused on clinical manufacturing.  This suite will significantly increase the company’s manufacturing capacity, with the potential to generate up to $30 million in additional revenue annually.  The company has secured a 25,000 square foot location in close proximity to its current campus and expects the new clinical suite to be complete and ready for clinical manufacturing activities by the first half of calendar 2017.    
  • In continued efforts to evolve into a fully integrated manufacturing business capable of efficiently meeting all of its clients’ needs, Peregrine is in the process of exploring additional service expansion opportunities.   

Drug Development Highlights:

  • The company will pursue a clinical development strategy focused on conducting small, early stage studies of bavituximab in combination with I-O agents.  These trials may be conducted as part of ongoing collaborations with AstraZeneca and the National Comprehensive Cancer Network (NCCN).  The goal of these trials will be to generate compelling data capable of driving partnering interest.  As part of this new strategy, the company has discontinued plans to initiate further Phase II and Phase III trials.  
  • The company continues to evaluate data from the SUNRISE trial in order to collect information that can best inform the ongoing clinical development of bavituximab.  As part of these efforts, Peregrine is working closely with AstraZeneca to identify the optimal strategy for the companies’ clinical development collaboration focused on combining bavituximab with AstraZeneca’s PD-L1 inhibitor, durvalumab.  It is expected that the initial trial in the collaboration will be a Phase I study evaluating the treatment combination in a range of solid tumors.  The expected timing of initiation of any trial will be determined by the continued collection of data from the SUNRISE trial and finalization of the trial design.  
  • Peregrine’s research collaboration with the NCCN, a not-for-profit alliance of 27 of the world’s leading cancer centers, is underway.  The NCCN is currently accepting proposals from its member institutions and their affiliate community hospitals to conduct clinical trials combining bavituximab with I-O agents for the treatment of a range of cancers.  It is expected that between two and five different clinical studies will be conducted as part of this collaboration, potentially providing Peregrine with a wealth of valuable human data to steer future development of bavituximab.  While specific timing has not been established, it is expected that the first studies will be initiated in late calendar year 2016 or early 2017.  
  • Peregrine’s ongoing preclinical research collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) continues to progress as planned. Researchers at MSKCC are evaluating novel combinations of bavituximab and other relevant I-O therapeutic approaches including checkpoint inhibitors, adoptive T-cell therapy and oncogenic virus, in multiple preclinical cancer models.  Initial data from these studies is expected to be presented at scientific conferences later in calendar year 2016.

Financial Strength Supporting Ongoing Activities

  • Peregrine remains in a strong financial position to continue to execute against its operational strategies for its contract manufacturing and drug developments businesses.  As of April 30, 2016, the company had $61 million in cash and cash equivalents. 

About Bavituximab: A Targeted Investigational Immunotherapy Bavituximab is an investigational chimeric monoclonal antibody that targets phosphatidylserine (PS). Signals from PS inhibit the ability of immune cells to recognize and fight tumors. Bavituximab is believed to override PS mediated immunosuppressive signaling by blocking the engagement of PS with its receptors as well as by sending an alternate immune activating signal.   PS targeting antibodies have been shown to shift the functions of immune cells in tumors, resulting in multiple signs of immune activation and anti-tumor immune responses. 

About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals, Inc. is a company focused on continued revenue growth from its contract manufacturing business and developing its novel immuno-oncology products.  The company is working to evaluate its lead immunotherapy candidate, bavituximab, in combination with a range of novel immuno-oncology (I-O) agents for the treatment of various cancers.  Peregrine’s in-house cGMP manufacturing capabilities are provided through its wholly-owned subsidiary Avid Bioservices, Inc. ( www.avidbio.com ), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com .

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that data from future immuno-oncology trials are not consistent with the company’s translational and preclinical data, the risk that one or more of the company’s immuno-oncology collaborators  terminates its collaboration, the risk that the results from the company’s contemplated immuno-oncology trials does not support further development of bavituximab, the submission of a Biologics License Application or drive partnership interest, the risk that the company may not have or raise adequate financial resources from debt and/or equity financings and/or Avid’s manufacturing operations to fund the further development of bavituximab, the risk that Avid's revenue growth may slow or decline, the risk that the company does not achieve ongoing profitability in 24 months, the risk that Avid may experience technical difficulties in processing customer orders which could delay delivery of products to customers and receipt of payment, and the risk that one or more existing Avid customers terminates its contract prior to completion . The company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2015 as well as any updates to these risk factors filed from time to time in the company's other filings with the Securities and Exchange Commission. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.  

CONTACT: Contacts: Jay Carlson Peregrine Pharmaceuticals, Inc. (800) 987-8256 info@peregrineinc.com Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 176

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 143

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 142

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 214

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 76

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 198

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading

Top 5 Most Recently Viewed Articles

Breaker’s TruSend™: A Game Changer in Email Marketing

Updated Category News Views 142

Breaker’s TruSend™: A Game Changer in Email Marketing In the fast-evolving world of marketing, email continues to hold its ground as a vital communication tool. Breaker has recognized the challenges marketers face with fragmented tech stacks and has introduced TruSend™, a robust email distribution platform. This innovation streamlines the email marketing process,...

Continue Reading
DigiKey and Qorvo Collaborate to Enhance Global Distribution

Updated Category News Views 151

DigiKey and Qorvo Forge Strategic Distribution Partnership DigiKey, a prominent global distributor known for its vast selection of technical components and automation products, has entered into a vital distribution agreement with Qorvo®, a leader in connectivity and power solutions. This collaboration aims to boost the availability and delivery speed of Qorvo's...

Continue Reading
Lloyds Bank's Financial Insights for 2025: A Comprehensive Review

Updated Category News Views 345

Overview of Lloyds Bank plc's 2025 Half-Year Results Lloyds Bank plc, a prominent player in the financial services sector, has released its half-year results for 2025, demonstrating resilience and strategic agility. As a member of the Lloyds Banking Group, it continues to show its commitment to delivering value to its stakeholders and customers. Key Financial Highlights...

Continue Reading
Advansor's Latest CO2 Enclosure Solutions Revolutionize Climate Control

Updated Category News Views 97

Advansor Introduces a New Range of CO2 Enclosures Advansor, a leading name in climate solutions, has recently unveiled an innovative line of CO2 enclosures tailored for supermarkets, cold storage facilities, and industrial applications. These enclosures are designed to simplify on-site installations and offer flexible options for outdoor placement. This groundbreaking...

Continue Reading
LG Innotek's Revolutionary Automotive AP Module Enhances Mobility

Updated Category News Views 220

LG Innotek's Innovative Entry into Automotive Semiconductor Market LG Innotek has taken a significant step into the automotive semiconductor component market with the launch of its Automotive Application Processor Module (AP Module). This move comes in response to a growing demand for sophisticated automotive technologies, particularly in the realm of Advanced Driver...

Continue Reading